Bimeda® Inc. announced today the release of KetoMed™ (ketoprofen) (ANADA 200 – 625) for the alleviation of inflammation and pain associated with musculoskeletal disorders in horses. This launch marks the first U.S. Food and Drug Administration (FDA) approved generic Ketofen™ Injection (ketoprofen) to become available.
"KetoMed is a great addition to Bimeda's equine products. We have taken immense pride in providing superior products to the industry for many years. Now we are excited to bring not only the first FDA approved generic Ketoprofen to the US market, but with desirable shatterproof bottles" Gavin Tierney, Bimeda CEO, commented.
Bimeda will launch KetoMed that is supplied in 50 mL and 100 mL multidose shatterproof bottles. The recommended dosage is 1 mg/lb (1 mL/100 lbs) of body weight once daily.
In gaining approval for KetoMed from the FDA, Bimeda was granted the same label claims as Ketofen. They contain the same active ingredient (ketoprofen) in the same concentration and dosage form, contain no inactive ingredients that may significantly affect the bioavailability of the active ingredient, and use the same route of administration. KetoMed meets the same quality and safety requirements and is manufactured at Bimeda's approved FDA facility.
This announcement is an exciting advancement for both vets and equine owners alike and Bimeda is honored to continue being at the forefront of developing revolutionary products for the industry.
Bimeda is a leading global manufacturer, marketer and distributor of animal health products and veterinary pharmaceuticals. Bimeda US headquarters are based in Oakbrook Terrace, Illinois. Bimeda is focused on providing a comprehensive, customer-driven service and selling consistently high-quality products at a market-conscious price level.